Dr Shila Mekhoubad, PhDSenior Director, Biology at Trace NeuroscienceSpeaker
Profile
Shila Mekhoubad is head of Biology at Trace Neurosicence. Before that she led the cellular modeling group and the UNC13A ASO program at Maze Therapeutics. Previously she was at Biogen where her work supported several ALS and SMA drug discovery programs including Biogen’s Tofersen (SOD1-ALS), BIIB078 (C9ORF72-ALS), and the clinically approved ASO Spinraza for spinal muscular atrophy. Shila received her Bachelor’s degree in Molecular, Cell and Developmental Biology from UCLA. She completed her Ph.D. at Harvard University, where she trained in the laboratory of Dr. Kevin Eggan, working on the utility of iPSCs for disease modeling of neurological disorders.
Agenda Sessions
Correcting Aberrant Splicing of UNC13A As a Treatment for People with ALS
, 2:00pmView Session